According to Zhitong Finance App, Prorow Pharmaceutical (000739.SZ) issued an announcement. Recently, Zhejiang Projiayuan Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Marketing Application for Chemical Ingredient” for the active ingredient deuterium enzalutamide issued by the State Drug Administration. Hainaan® (deuterium enzalutamide softgels) is a novel androgen receptor (AR) inhibitor developed by Haichuang Pharmaceutical Co., Ltd. based on its deuterium-derived drug development platform. The drug was approved for marketing by the State Drug Administration in May 2025, then included in the 2025 edition of the “CSCO Prostate Cancer Diagnosis and Treatment Guidelines” in the comprehensive recommended treatment plan for mCRPC, and included in the national medical insurance drug catalogue in December 2025.

This time, deuterium enzalutamide API obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients”, which fully demonstrates the company's comprehensive competitiveness in CDMO business R&D, production and system support, and will have a certain positive impact on the company's future operations; it will also strongly guarantee the supply of deuterium enzalutamide APIs and help partners promote product development and benefit patients.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.